Clinical Management of Tuberous Sclerosis Complex

Clinical management of tuberous sclerosis complex (TSC) demands a coordinated, lifelong approach that addresses its multisystem manifestations. Early diagnosis often relies on genetic testing for TSC1 or TSC2 mutations, complemented by imaging studies to detect cortical tubers, subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM). Surveillance protocols recommend regular neuroimaging, renal ultrasound, pulmonary function testing and dermatological assessment to guide intervention timing. Epilepsy is managed with antiepileptic drugs or early targeted therapy, including vigabatrin for infantile spasms, while mTORC1 inhibitors such as sirolimus and everolimus have become standard treatments to reduce tumour burden and stabilise neurological and renal lesions. Interdisciplinary teams address TSC-associated neuropsychiatric disorders (TAND), ensuring neurodevelopmental screening and psychosocial support. Surgical resection remains an option for refractory SEGAs or life-threatening angiomyolipomas, whereas emerging biomarker strategies aim to personalise therapy and predict seizure onset. Through harmonised guidelines and patient registries, clinicians now balance prophylactic interventions, targeted pharmacotherapy and symptom-driven procedures to optimise quality of life and long-term outcomes.

Research from Nature Portfolio

Recent multi-omic analyses of infants with TSC have revealed early biomarkers predictive of epilepsy development and demonstrated that pre-symptomatic treatment with vigabatrin markedly alters metabolic and proteomic profiles, improving seizure prognostication. Such findings support biomarker-guided intervention to prevent or delay onset of seizures. Complementing this, comprehensive genomic profiling of TSC-related hamartomas has mapped the low somatic mutation burden across organ systems and identified conserved molecular signatures, including neuroinflammatory pathways in brain lesions. This molecular atlas offers a foundation for precision medicine approaches by linking lesion genotype to clinical phenotype and potential therapeutic targets.

Clinical Management of Tuberous Sclerosis Complex publication trend

The graph below shows the total number of articles in clinical management of tuberous sclerosis complex across all publications each year (not limited to Nature Index journals).

Technical terms

mTORC1: A cell-growth regulatory complex hyperactivated in TSC that drives tumour formation and metabolic changes.

Vigabatrin: An antiepileptic agent that irreversibly inhibits GABA transaminase, used prophylactically to prevent infantile spasms.

Subependymal giant cell astrocytoma (SEGA): A benign, slow-growing brain tumour arising near the ventricles, requiring regular imaging and potential surgical or pharmacological intervention.

Lymphangioleiomyomatosis (LAM): A rare lung disease characterised by cystic destruction due to invasive smooth muscle-like cells harbouring TSC mutations.

Renal angiomyolipoma: A benign kidney tumour composed of blood vessels, smooth muscle and fat, prone to haemorrhage and responsive to mTOR inhibitors.

References

1. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology (2013).
2. Molecular EPISTOP, a comprehensive multi-omic analysis of blood from Tuberous Sclerosis Complex infants age birth to two years. Nature Communications (2023).
3. The genomic landscape of tuberous sclerosis complex. Nature Communications (2017).
4. Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition. Advanced Science (2023).
5. Astroglial calcium signaling and homeostasis in tuberous sclerosis complex. Acta Neuropathologica (2024).
6. TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients. Orphanet Journal of Rare Diseases (2017).
7. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet Journal of Rare Diseases (2018).
8. Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease. PLOS ONE (2011).
9. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLOS ONE (2016).
10. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLOS ONE (2017).